Consensus in infection complications
DOI:
https://doi.org/10.46765/2675-374X.2025v6n1e311Keywords:
Hematopoietic Stem Cell Transplantation, Drug Resistance, Virus Diseases, Delivery of Health CareAbstract
Infectious complications remain a leading cause of morbidity and mortality in pediatric recipients of hematopoietic stem cell transplantation (HSCT). In Brazil, the access to effective therapies for multidrug-resistant bacterial, invasive fungal, and viral infections is frequently limited in the public healthcare system (SUS), posing significant challenges to optimal clinical management. This consensus-based review, endorsed by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation, focuses on selected pediatric infectious complications in HSCT for which access to appropriate antimicrobial therapy remains particularly restricted. We summarize recommended antimicrobial agents for multidrug-resistant bacterial infections, invasive fungal diseases, and viral infections, highlighting discrepancies between evidence-based treatment strategies and drug availability in the SUS.
References
1. Brasil. Ministério da Saúde. Obter medicamentos para a população do estado ou município. Brasília: Ministério da Saúde; 2025. Available at: https://www.gov.br/pt-br/servicos/obtermedicamentos-para-a-populacao-do-estado-ou-municipio
2. Hoshino WT, da Silva AMPS, Pignatari AC, Gales AC, Carlesse F. Experience in Ceftazidime-Avibactam for treatment of MDR BGN infection in oncologic children. Braz J Infect Dis. 2025;29(2):104515. https://doi.org/10.1016/j.bjid.2025.104515 DOI: https://doi.org/10.1016/j.bjid.2025.104515
3. Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, de Waele J, Daikos GL, Akova M, Harbarth S, Pulcini C, Garnacho-Montero J, Seme K, Tumbarello M, Lindemann PC, Gandra S, Yu Y, Bassetti M, Mouton JW, Tacconelli E, Rodríguez-Baño J. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect. 2022;28(4):521–47. https://doi.org/10.1016/j.cmi.2021.11.025 DOI: https://doi.org/10.1016/j.cmi.2021.11.025
4. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde e Ambiente. Departamento de HIV/AIDS, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis. Coordenação-Geral de Vigilância da Tuberculose, Micoses Endêmicas e Micobactérias não Tuberculosas. Nota informativa nº 9/2023-CGTM/DATHI/SVSA/MS. Orientações acerca da disponibilidade dos medicamentos antifúngicos para o tratamento das micoses endêmicas e oportunistas e o fluxo para requisição dos medicamentos. Brazil: Ministério da Saúde; 2023.
5. Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367–76. https://doi.org/10.1093/cid/ciz1008 DOI: https://doi.org/10.1093/cid/ciz1008
6. Kobayashi C, Hanadate T, Niwa T, Hirano Y, Yoshiyasu T, So M, Matsui K. Safety and efficacy of micafungin for prophylaxis against invasive fungal infections in Japanese patients undergoing hematopoietic stem cell transplantation: Results of a post-marketing surveillance study. J Infect Chemother. 2015;21(6):438–43. https://doi.org/10.1016/j.jiac.2015.01.016 DOI: https://doi.org/10.1016/j.jiac.2015.01.016
7. Fernández Ledesma B, Mendoza-Palomar N, Melendo Pérez S, Fernández-Polo A, Renedo Miró B, Pau Parra A, Luque Pardos S, Grau Cerrato S, Vima Bofarull J, Martín-Gómez MT, Pujol Jover M, Benítez Carbante MI, Díaz de Heredia C, Soler-Palacin P. Isavuconazole use and TDM in real-world pediatric practice. Antimicrob Agents Chemother. 2023;67(12):e0082923. https://doi.org/10.1128/aac.00829-23 DOI: https://doi.org/10.1128/aac.00829-23
8. Von Lilienfeld-Toal M, Khawaja F, Compagno F, Robin C, Piñana JL, Cesaro S, Einsele H, Ljungman P, Navarro D, Boeckh M, Chemaly RF, Hirsch HH. Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia. Lancet Infect Dis. 2025: S1473-3099(25)00365-2. https://doi.org/10.1016/S1473-3099(25)00365-2 DOI: https://doi.org/10.1016/S1473-3099(25)00365-2
9. Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, González Del Castillo J, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Rodríguez Fernandez R, Kestler M, Bouza E. Respiratory syncytial virus: A new era. Rev Esp Quimioter. 2024;37(2):134–48. https://doi.org/10.37201/req/147.2023 DOI: https://doi.org/10.37201/req/147.2023
10. Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sánchez PJ, Kotton CN, Mahon BE, Meyer S, Long SS, McMorrow ML. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(34):920–5. https://doi.org/10.15585/mmwr.mm7234a4 DOI: https://doi.org/10.15585/mmwr.mm7234a4
11. Domachowske J, Hamrén UW, Banu I, Baronio R, Basavaraju B, Koen A, Leach A, Mankad VS, Pannaraj PS, Soler-Palacin P, Takas T, Mori M, Villafana T; MUSIC Study Group. Safety and pharmacokinetics of nirsevimab in immunocompromised children. Pediatrics. 2024;154(4):e2024066508. https://doi.org/10.1542/peds.2024-066508 DOI: https://doi.org/10.1542/peds.2024-066508
12. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde e Ambiente. Departamento de HIV/AIDS, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis. Coordenação-Geral de Vigilância da Tuberculose, Micoses Endêmicas e Micobactérias não Tuberculosas. Nota técnica nº 7/2024-CGTM/DATHI/ SVSA/MS. Brazil: Ministério da Saúde; 2024.
13. Piret J, Boivin G. Management of cytomegalovirus infections in the era of the novel antiviral players, letermovir and maribavir. Infect Dis Rep. 2024;16(1):65–82. https://doi.org/10.3390/idr16010005
14. Khawaja F, Zamora D, Yong MK, Hakki M, Goscicki BK, Danziger-Isakov L, Lin A, Carpenter PA, Boeckh M, Papanicolaou GA, Dadwal SS, Chemaly RF. American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy Recipients. Transplant Cell Ther. 2025;31(10):727–41. https://doi.org/10.1016/j.jtct.2025.06.025 DOI: https://doi.org/10.1016/j.jtct.2025.06.025
15. Vendemini F, De Lorenzo P, Romani F, Malandrin SMI, Verna M, Bonanomi S, Valsecchi MG, Lucchini G, Balduzzi A. Letermovir primary and secondary prophylaxis in pediatric recipients of allogeneic haematopoietic stem cell transplant. Transplant Cell Ther. 2025;31(9):699.e1–e11. https://doi.org/10.1016/j.jtct.2025.05.021 DOI: https://doi.org/10.1016/j.jtct.2025.05.021
16. Aldalati AY, Hussein AM, Balbaa E, Hammadeh BM, Idrees M, Aloudat O, Albliwi M, Abuassi M, Sultan I. Efficacy and safety of letermovir for cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation recipients: a systematic review, meta-analysis, and meta-regression. Transpl Infect Dis. 2025;27(2):e70006. https://doi.org/10.1111/tid.70006 DOI: https://doi.org/10.1111/tid.70006
17. Körholz KF, Füller MA, Hennies M, Holterhus M, Hagedorn S, Ahlmann M, Thorer H, Burkhardt B, Groll AH. Letermovir for prophylaxis and pre-emptive therapy of cytomegalovirus infection in paediatric allogeneic haematopoietic cell transplant patients. Paediatr Drugs. 2023;25(2):225–32. https://doi.org/10.1007/s40272-022-00547-6 DOI: https://doi.org/10.1007/s40272-022-00547-6
18. Kuhn A, Puttkammer J, Madigan T, Dinnes L, Khan S, Ferdjallah A, Kohorst M. Letermovir as cytomegalovirus prophylaxis in a pediatric cohort: a retrospective analysis. Transplant Cell Ther. 2023;29(1):62.e1–e4. https://doi.org/10.1016/j.jtct.2022.10.005 DOI: https://doi.org/10.1016/j.jtct.2022.10.005
19. Valencia Deray KG, Danziger-Isakov LA, Downes KJ. Current and emerging antiviral agents in the prevention and treatment of cytomegalovirus in pediatric transplant recipients. J Pediatric Infect Dis Soc. 2024;13 (Suppl.1):S14–S21. https://doi.org/10.1093/jpids/piad059 DOI: https://doi.org/10.1093/jpids/piad059
20. Piret J, Boivin G. Management of cytomegalovirus infections in the era of the novel antiviral players, letermovir and maribavir. Infect Dis Rep. 2024;16(1):65–82. https://doi.org/10.3390/idr16010005 DOI: https://doi.org/10.3390/idr16010005
21. Cesaro S, Porta F. Adenovirus infection in pediatric hematopoietic cell transplantation: a challenge still open for survival. J Clin Med. 2022;11(16):4827. https://doi.org/10.3390/jcm11164827 DOI: https://doi.org/10.3390/jcm11164827
22. Thomas SJ, Young RT, Steinbach WJ, Lugo DJ. Risks and outcomes of adenovirus disease in pediatric hematopoietic stem cell transplant recipients-Comparison of current antiviral treatment options. Transpl Infect Dis. 2021;23(2):e13505. https://doi.org/10.1111/tid.13505 DOI: https://doi.org/10.1111/tid.13505
23. Grasa C, Monteagudo-Vilavedra E, Pérez-Arenas E, Falces-Romero I, Mozo Del Castillo Y, Schüffelmann-Gutiérrez C, Del Rosal T, Méndez-Echevarría A, Baquero-Artigao F, Zarauza Santoveña A, Serrano Fernández P, Sainz T, Calvo C. Adenovirus infection in hematopoietic and solid organ paediatric transplant recipients: treatment, outcomes, and use of cidofovir. Microorganisms. 2023;11(7):1750. https://doi.org/10.3390/microorganisms11071750 DOI: https://doi.org/10.3390/microorganisms11071750
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Luiza de Souza Santos Milaré, Laura de Almeida Lanzoni, Fabianne Altruda de Moraes Costa Carlesse
This work is licensed under a Creative Commons Attribution 4.0 International License.
